Drug intelligence / Profile preview

DWC20152

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC20152 is a small molecule investigational drug developed by Daewoong Pharmaceutical. Its mechanism of action and therapeutic targets have not been disclosed publicly. The compound has undergone at least one Phase 1 clinical trial in healthy male volunteers to evaluate its pharmacokinetics and safety, in comparison with another investigational agent, DWC20151. As of the latest available information, there are no approved indications or known adverse events reported for this drug[1][2][3][5].

Beyond the preview

Go deeper on DWC20152.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC20152.

Explore the full profile